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Abstract The aim of the present study was to calculate non-
medical costs during year 1 after diagnosis in two cohorts of
patients with early rheumatoid arthritis enrolled 1996–1998
and 2006–2009. Clinical data were collected regularly in both
cohorts. Besides information about healthcare utilization and
days lost from work, patients reported non-medical costs for
aids/devices, transportation, formal and informal care. Formal
care was valued as full labour cost for official home help
(€42.80/h) and informal care from relatives and friends as
opportunity cost of leisure time, corresponding to 35% of
labour cost (€15/h). In both cohorts, only 2% used formal care,
while more than 50% used informal care. Prescription of
aids/devices was more frequent in cohort 2 and more women
than men needed aids/devices. Help with transportation was
also more common in cohort 2. Women in both cohorts need-
ed more informal care than men, especially with personal care
and household issues. Adjusting for covariates in regression
models, female sex remained associated with higher costs in
both cohorts. Non-medical costs in cohort 2 were €1892,
€1575 constituting informal care, corresponding to 83% of
non-medical costs. Total non-medical costs constituted 25%
of total direct costs and 11% of total direct and indirect costs.
Informal care accounted for the largest part of non-medical
costs and women had higher costs than men. Despite
established social welfare system, it is obvious that family
and friends, to a large extent, are involved in informal care
of patients with early RA, and this may underestimate the total
burden of the disease.
Keywords Cohort study . Disease activity . Early rheumatoid
arthritis . Gender . Health services research . Non-medical
costs
Rheumatoid arthritis (RA) is a chronic and disabling disease,
and the economic consequences of the disease are substantial
for patients and for society [1–3]. Costs caused by healthcare
utilization are high, but total costs have hitherto mainly been
driven by loss of working capacity [4]. The introduction of
biological drugs during the last decade has led to improved
management of the disease but has also substantially increased
direct costs, which are now predominantly driven by drug
costs [5, 6]. It has been suggested that the severity of the
disease is declining, possibly due to early diagnosis and
early treatment [7]. A decline in incidence, especially in
women has also been reported, as well as a shift towards
higher age at onset of disease [8]. By contrast, others have
reported an increase in RA-incidence in women and also an
increasing prevalence of RA [9].
We have previously reported the development of disease
activity and costs in a cohort of patients with early RA en-
rolled 1996–1998 (TIRA1, T1, acronym for ‘early interven-
tion in RA’) [3]. A newRA-cohort (TIRA2, T2), was launched
10 years later, 2006–2009, and is currently followed,
collecting clinical and health economic data, using similar
instruments and questionnaires as in the 1996–1998 cohort
[10]. All patients were assessed at baseline (time point of
inclusion), after 3 months and after 6 months and at 1-year
follow-up, by a team care unit with rheumatologist, physio-
therapist, occupational therapist and nurse, similarly in both
cohorts. No interventions were performed according to a study
protocol, and drug treatment decisions in both cohorts were
made by the physician’s preference after physical examina-
tion. Patients were also offered multiprofessional intervention
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when considered necessary. In addition, all patients were giv-
en the opportunity to participate in an educational programme
carried out by the multiprofessional team.
During the first year after diagnosis, the total costs in the
1996–1998 cohort amounted to €15,868, direct costs account-
ing for 30% and indirect costs 70% [3]. In the 2006–2009
cohort, there was a shift towards increasing direct costs and
decreasing indirect costs, with total costs remaining basically
unchanged, €15,358, direct costs accounting for 37% and in-
direct costs 63%. Days in hospital decreased in T2 compared
to T1, but costs for outpatient care and drugs increased. T2
patients had a substantially higher prescription of DMARDs
including biologics, compared to T1 patients, and the total
direct costs amounted to €5716 in T2 vs €4674 in T1. Sick
leave was lower in T2 compared to T1, but disability
pension was higher, resulting in basically unchanged total
loss of productivity [10].
From a healthcare perspective, direct costs typically in-
clude costs for outpatient visits, hospitalization, surgery and
drugs, while adopting a societal perspective, relevant non-
medical costs such as costs for medical aids, assistive devices,
transportation, formal and informal care, regardless payer,
should also be included [11]. There is no general consensus
on which perspective should be adopted, and in our previous
reports, as well as in many other reports, non-medical costs
have not been included in the cost calculations [12–14].
The aim of the present study was to calculate the non-
medical costs during the first year after diagnosis in two sim-
ilar cohorts of patients with early RA, enrolled 10 years apart,
from basically the same catchment area.
Patients and methods
Patients
During 1996–1998, 320 patients with early (≤1 year) RAwere
recruited from 10 rheumatology units in Sweden, correspond-
ing to a catchment area of >1 million inhabitants (TIRA1, T1,
acronym for ‘early intervention in RA’). A similar cohort,
TIRA2 (T2), was launched 10 years later, and 463 patients
with early RAwere enrolled 2006–09.
Clinical assessments
Clinical and laboratory data was collected regularly in
both cohorts. The 28-joint-count disease activity score
(DAS28) was calculated [15], and patients reported pain
on a VAS-scale and completed the Health Assessment
Questionnaire (HAQ) [16]. Details of the study are de-
scribed previously [3].
Health economic questionnaire
Besides a baseline questionnaire with sociodemographic data
including age, sex, marital status, educational level and em-
ployment status, patients in both cohorts were provided with
health economic questionnaires every 6 months. The ques-
tionnaires were kept as diaries, and patients reported continu-
ously all health care utilization and number of days lost from
work. The health related quality-of-life instruments EQ-5D
and EQ-VAS (0–100) were also completed [17]. In addition,
patients also reported non-medical costs such as costs for aids
and devices, transportation, formal and informal care. Aids
and devices were divided into 4 subgroups: (1) aids for per-
sonal care and activities of daily living (ADL) and household
appliances, (2) orthoses such as collars, splints, insoles and
shoes, (3) canes and crutches and (4) work adaptation aids
such as modified chairs and desks. Pricing of aids and devices
were obtained from companies and suppliers providing these
devices (www.gulare.com, http://plus.rjl.se). Transportation,
regardless mode of travel, be it somebody driving or using
public transportation, was reported as the patient’s expenses
for the trips or as a calculation of the travel distance, using
official tariffs for costs per kilometre (www.trafa.se, www.
fardtjansten.sll.se). Formal care was valued as full labour
cost for official community home help (€42.80/h) (www.skl.
se), while cost for informal care from relatives and friends was
valued as the opportunity cost of leisure time, corresponding
to 35% of full labour cost (€15/h). The questionnaire in T2
was slightly revised compared to the questionnaire in T1, but
basically similar questions were asked.
Healthcare in Sweden is tax-financed, and apart from
minor co-payments, basically all medical and non-medical
costs, except informal care, are included in the welfare
system, with almost full coverage of healthcare services.
Costs in the first cohort were calculated, using unit costs
from 2001, inflation adjusted to 2013, using the Swedish
Consumer Price Index (CPI), and in the second cohort,
unit costs from 2009, inflation-adjusted to 2013 with
CPI. All costs were converted to 2013 euros, using the
average exchange rate in 2013, €1 = 8.6494 SEK (www.
riksbank.se). Costs were calculated, applying a societal
perspective, including all costs, regardless payer.
Statistics
Data are presented using descriptive statistics. Continuous
variables are reported as means with standard deviations
(SD) and categorical variables as numbers and proportions.
Differences were analysed by Student’s t test, chi-square test
or Fishers exact test when appropriate. Multivariate linear and
logistic regression analyses were performed to explain non-
medical costs and utilization of non-medical care, adjusting
for covariates in the two cohorts and in women and men
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separately. Level of significance was set at p < 0.05. All anal-
yses were performed using IBM SPSS 20.0.
Ethical considerations
All patients gave written informed consent to participation.
The study protocol was approved by the local ethics commit-
tee in Linkoping (Dnr M 168-05).
Results
Patients
Complete health economic questionnaires were available in
276/320 (86%) patients, 68% women in T1 and in 340/463
(73.4%) patients, and 70% women in T2 at 1-year follow-
up. There were no differences in age, educational level,
marital status, levels of sick leave and disability pension
between patients with health economic data and patients
with missing data.
Patients included in the present study had similar clinical
characteristics at inclusion, except for women in T2, being
older and reporting more pain and higher EQ-5D.Women also
had slightly longer education, 11 vs 10.6 years, but there were
no differences in DAS28 and HAQ between the cohorts
(Table 1).
Utilization of non-medical care
Only 2% of the patients used formal care during the first year
after diagnosis, with no difference between the cohorts. The
use of informal care was, however, much larger. More than
50% of patients in both cohorts needed help from relatives and
friends with various issues. The informal caregivers provided,
by far, most help with household activities such as cleaning,
cooking, washing clothes, shopping and carrying heavy items,
but also help with personal care such as dressing, eating and
help with bathing and showering. A number of patients also
needed help with outdoor activities such as gardening and
snow shovelling. More women than men needed informal
care, especially concerning household activities, 56.7% wom-
en vs 23.6% men in T1 (p < 0.001) and 57.3% women vs
30.7% men in T2 (p < 0.001). In T2, more women needed
help with personal care, 25.5% women vs 9.9% men
(p = 0.001) (Table 2 and Table 3).
Total prescription of aids and devices was more frequent in
T2 compared to T1, 38.8 vs 18.5% (p < 0.001). Prescription of
devices facilitating everyday activities of daily living (ADL)
was consistently higher in women than in men. Women were
also to a higher extent prescribed orthoses, splints and ortho-
paedic footwear. Only few patients used canes or crutches in
T2. As the specific question about walking aids was not asked
for in T1, comparisons cannot be made. On the other hand,
workplace adjustments paid for by the employer was reported
in T1, but not in T2. Such adjustments, like special chairs and
height adjustable desks, were available for 4.7% of patients in
T1, the vast majority women.
Costs for transportation were high in both cohorts, similar-
ly in men and women, but the proportion of patients needing
help with transportation was significantly larger in T2, 63.5 vs
40.6% in T1 (p < 0.001) (Table 2 and Table 3).
Costs of non-medical care
Proportion of patients using formal care was similar in the two
cohorts, and there was no significant difference in costs. Total
prescription of aids and devices was higher in T2, but average
total costs did not differ between the cohorts. A large amount
of basic inexpensive assistive devices, such as grab bars, loop
scissors and grippers, were prescribed to many patients in T2,
and this lowered average costs.
Costs for orthoses were significantly higher in T2. Orthoses
for wrists, elbows and hands were frequently prescribed as
well as knee braces and foot orthoses. Orthopaedic custom-
moulded insoles and pads were often prescribed early in the
disease course, and in some cases, patients were prescribed
orthopaedic shoes, when pads and insoles did not have suffi-
cient effect. Prescription of canes or crutches was reported
only in T2, but was only used by 14 patients, and accordingly,
average costs were low. Thirteen patients in T1 were provided
with various ergonomic aids, for instance, height adjustable
desks, at the employer’s expense. Although this was limited to
few patients, the individual cost for each patient was rather
high. Costs for transportation did not differ between the co-
horts. More patients in T2 needed help with transportation, but
the travelled distances for T2 patients were shorter, and this
lowered the average costs (Table 4 and Table 5).
Costs for informal care are presented separately, since the
information on informal care differed between the cohorts. In
T1, patients reported if they had used any informal help and if
so, what kind of help, but no information on the extent of help,
i.e. number of hours needed. In T2, similar information was
available, but in addition, T2 patients also provided detailed
information about the number of hours with help, they had
received each week or month. Hence, the proportion of pa-
tients needing informal care is available for both cohorts, but
costs could be calculated only for the T2 cohort. During the
first year, in the T2 cohort, women needed help on the average
132 h compared to men, who needed only 40 h (p < 0.000).
The costs for informal care in T2 amounted to €1575, which is
5 times higher than total costs for remaining non-medical
costs in T2 (Table 4 and Table 5).
The proportion of total non-medical costs, including infor-
mal care, amounted to 11% of total costs, with 9% accounting
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for informal care. The costs and proportions of costs for T2
patients are presented in Fig. 1.
In logistic and linear regression analyses, adjusting for age,
gender, marital status, education, DAS28, HAQ, pain and EQ-
5D, female sex was still significantly associated with higher
costs for aids and devices and informal care in both cohorts
and utilization of non-medical care was associated with fe-
male sex and cohort (data not shown).
Discussion
Non-medical costs are often excluded in cost calculations, but
for RA-patients, costs for medical aids, assistive devices,
transportation, formal and informal care can be considerable
[18]. In the present study, we have calculated non-medical
costs in two cohorts of RA-patients, enrolled 10 years apart.
In the latter cohort, T2, the non-medical costs, excluding in-
formal care, were twice the size compared to the first cohort,
T1. However, comparing these costs with previous calcula-
tions of direct and indirect costs in the 2 cohorts, the non-
medical costs, excluding informal care, were small and had
minor impact on the proportions, representing only 1 and 2%
respectively of total costs [3, 10].
When costs for informal care were included in total non-
medical costs, the proportions grew and increased from 2 to
11% of total costs and from 5% of direct costs to 25%. Since
information on number of hours was available only in T2,
costs for informal care could be calculated only in T2.
However, since the proportion of patients using informal care
Table 2 Proportion of patients (%) using formal and informal care, transportation and aids and devices during the first year. Differences between the 2
cohorts as well as between women and between men in the 2 cohorts respectively
Total p Women p Men p
T1 T2 T1 T2 T1 T2
n = 276 n = 340 n = 187 n = 239 n = 89 n = 101
Formal care 2.2 2.1 0.921 2.7 2.1 0.754 1.1 2.0 1.00
Aids/devices total 18.5 38.8 <0.000 21.4 45.6 <0.000 12.4 22.8 0.062
ADL devices 8.7 19.1 <0.000 10.2 23.4 <0.000 5.6 8.9 0.386
Orthoses 9.4 28.8 0.001 10.7 33.5 <0.000 6.7 17.8 0.022
Walking aids NA 4.1 – NA 4.6 – NA 3 –
Work adaptation 4.7 NA – 6.4 NA – 1.1 NA –
Transportation 40.6 63.5 <0.000 42.2 63.6 <0.000 37.1 63.4 <0.000
Informal care 51.4 52.4 0.823 59.4 60.3 0.852 34.8 33.7 0.866
Personal care 19.9 20.9 0.770 19.3 25.5 0.126 21.3 9.9 0.029
Household 46.0 49.4 0.401 56.7 57.3 0.895 23.6 30.7 0.274
ADL activities of daily living, including devices for personal care and household, NA not applicable
Table 1 Baseline characteristics of T1 and T2 at inclusion and p value for differences between the cohorts, differences between women in T1 and T2
and differences between men in T1 and T2
Total Women Men
T1 T2 p T1 T2 p T1 T2 p
n = 276 n = 340 n = 187 n = 239 n = 89 n = 101
Age (yrs) 56 (15) 59 (14) 0.019 54 (15) 58 (13) 0.013 60 (13) 62 (14) 0.481
Cohabiting (%) 73 73 0.978 70 71 0.961 78 78 0.979
Education (yrs) 10.6 (2.1) 11.0 (2.3) 0.025 10.7(2.1) 11.2 (2.3) 0.050 10.3(2.0) 10.6(2.1) 0.351
DAS28 5.3 (1.2) 5.1 (1.3) 0.102 5.3 (1.2) 5.2 (1.2) 0.305 5.3 (1.0) 5.0 (1.4) 0.154
HAQ (0–3) 0.9 (0.6) 1.0 (0.6) 0.094 0.9 (0.6) 1.0 (0.6) 0.090 0.8 (0.5) 0.8 (0.6) 0.715
Pain (VAS) 48 (25) 53 (25) 0.017 48 (24) 54 (24) 0.030 47 (26) 51 (26) 0.310
EQ5D (0–1) 0.59 (0.26) 0.55 (0.27) 0.107 0.60(0.25) 0.55(0.27) 0.044 0.57(0.27) 0.57(0.28) 0.966
EQ-VAS (0–100) 58 (19) 57 (21) 0.478 59 (20) 56 (21) 0.176 58 (19) 60 (20) 0.397
DAS28 28 joint disease activity score, HAQ Health Assessment Questionnaire, VAS visual analogue scale, EQ-5D EuroQol 5-Dimensions, EQ-VAS
general health, visual analogue scale
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was similar in both cohorts, 51.4 and 52.4%, respectively, we
believe that costs for informal care in T1 are likely to be of the
similar magnitude in T1 as in T2.
Direct comparisons between various studies are hazardous
since healthcare systems differ between countries, depending
on various social systems and availability of healthcare.
Levels of remuneration differ, and availability of aids and
devices as well as formal care can be limited. Bearing this in
mind, some comparisons can still be made.
In a Belgian study, informal care, valued at €8.70/h, made
up for 51% of total direct costs [19]. This is higher than in our
study, even though our price per hour is higher (€15/h), but
could be explained by the Belgian study, including informal
care for all causes, while our costs were limited to RA-related
costs. A French study reported that total non-medical costs
made up for 29% of total direct costs [13] which is close to
our 25%. The French study, however, valued informal care by
the replacement method, using the hourly rate of formal home
help, while in the present study, informal care was valued as
the opportunity cost of leisure time, corresponding to 1/3 of
cost for formal home help. In a study from Italy, Turchetti et al.
[20] estimated that informal care made up for 84% of total
non-medical costs and this is in line with our results, where
informal care made up for 83% of total non-medical costs. In a
systematic review, Lundkvist et al. reported that total non-
medical costs in Sweden made up for 29% of direct costs,
Table 4 Non-medical costs (€, mean, SD) during the first year in T1 and T2. Differences between the two cohorts as well as between women and
between men in T1 and T2, respectively
Total p Women p Men p
T1 T2 T1 T2 T1 T2
n = 276 n = 340 n = 187 n = 239 n = 89 n = 101
Formal care 20 (247) 148 (1591) 0.145 8 (49) 182 (1859) 0.202 45 (429) 67 (587) 0.772
Aids/devices total 62 (264) 74 (154) 0.504 73 (289) 87 (168) 0.523 41 (201) 43 (109) 0.936
ADL devices 29 (209) 20 (78) 0.486 32 (226) 24 (89) 0.621 21 (167) 10 (45) 0.528
Orthoses 14 (61) 47 (101) <0.000 17 (71) 55 (104) <0.000 8 (34) 29 (90) 0.041
Walking aids – 7 (45) – 9 (50) – 4 (30)
Work adaptation 20 (129) – 24 (137) – 12 (110) –
Transportation 68 (143) 95 (417) 0.303 72 (150) 110 (493) 0.304 61 (128) 60 (97) 0.967
Totala 151 (399) 317 (1965) 0.167 152 (353) 379 (2303) 0.183 147 (483) 170 (663) 0.786
Informal care – 1575 (3240) – 1989 (3717) – 596 (1149)
Totalb – 1892 (3991) – 2368 (4599) – 766 (1356)
– not assessed
ADL activities of daily living, including aids/assistive devices for personal care and household
a Total non-medical costs excluding informal care
b Total non-medical costs including informal care
Table 3 Proportion of patients
(%) using formal and informal
care, transportation and aids and
devices during the first year.
Differences between women and
men in T1 and between women
and men in T2
T1 p T2 p
Women Men Women Men
n = 187 n = 89 n = 239 n = 101
Formal care 2.7 1.1 0.668 2.1 2.0 1.00
Aids/devices total 21.4 12.4 0.071 45.6 22.8 <0.000
ADL devices 10.2 5.6 0.211 23.4 8.9 0.002
Orthoses 10.7 6.7 0.293 33.5 17.8 0.004
Walking aids NA NA – 4.6 3 0.776
Work adaptation 6.4 1.1 0.067 NA NA –
Transportation 42.2 37.1 0.414 63.6 63.4 0.968
Informal care 59.4 34.8 <0.000 60.3 33.7 <0.000
Personal care 19.3 21.3 0.684 25.5 9.9 0.001
Household 56.7 23.6 <0.000 57.3 30.7 <0.000
ADL activities of daily living, including devices for personal care and household, NA not assessed
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which is close to our 25 and 14% of total costs and this is also
close to our 11% [21].
There are many difficulties in estimating the value of infor-
mal care, in both quantifying the number of hours used and
valuing the hours. The main methods used for quantifying the
time for informal caregiving are the diary method and the
recall method. Comparative studies have shown that the recall
method may give a higher estimate of informal care hours
[22]. In addition, when the informal caregiver performs activ-
ities that benefit himself while providing informal care, joint
production occurs and this should preferably be deducted
from the cost of informal care. This information was,
however, not available and could not be taken into account
in the present study.
When estimating the value of an hour of informal care,
there are different theoretical approaches, as well as a variety
in how these approaches are applied. The opportunity cost
method calculates the costs of informal care as the value of
the best alternative use of the time used for informal care. If
the caregiving hours could be used for formal (paid) produc-
tion, the value of informal care is equal to the value of this
production. If the informal caregiver uses his or her leisure
time, the cost of informal care is equal to the value of this
leisure time. An alternative to the opportunity cost method is
the replacement cost method or shadow price, which means
that the value of the informal care is given by the cost of hiring
formal care, adjusting for different efficiency between infor-
mal and formal care [23]. In the present study, we have based
the value estimate on the opportunity cost method, assuming
that the informal care providers mainly used leisure time,
making a rather conservative assumption that leisure time
can be valued at 35% of full labour cost (€15/h). In a recent
study, trying to attribute a monetary value of patients’ leisure
time (not participating in the labour market), travel time and
treatment time were valued at approximately €13/h, which is
basically in line with our valuation [24].
Despite the various methods of calculating costs, costs for
informal care often represent the largest part of total non-
medical costs [21, 25]. In the present study, informal care
had by far the largest impact on total non-medical costs and
made up for costs that were 5 times higher than all other non-
medical costs together.Women needed significantly more care
with household issues in both cohorts and in T2, also more
help with personal care. This could indicate that women were
Table 5 Non-medical costs (€,
mean, SD) during the first year in
T1 and T2. Differences between
women and men in T1 and
between women and men in T2
T1 p T2 p
Women Men Women Men
n = 187 n = 89 n = 239 n = 101
Formal care 8 (49) 45 (429) 0.239 182 (1859) 67 (587) 0.545
Aids/devices total 73 (289) 41 (201) 0.346 87 (168) 43 (109) 0.015
ADL devices 32 (226) 21 (167) 0.688 24 (89) 10 (45) 0.137
Orthoses 17 (71) 8 (34) 0.233 55 (104) 29 (90) 0.031
Walking aids – – 9 (50) 4 (30) 0.365
Work adaptation 24 (137) 12 (110) 0.477 – –
Transportation 72 (150) 61 (128) 0.554 110 (493) 60 (97) 0.312
Totala 152 (353) 147 (483) 0.913 379 (2303) 170 (663) 0.371
Informal care – – 1989 (3717) 596 (1149) <0.000
Totalb – – 2368 (4599) 766 (1356) <0.000
– not assessed
ADL activities of daily living, including aids/assistive devices for personal care and household
a Total non-medical costs excluding informal care











Fig. 1 Direct costs, indirect costs and non-medical costs and proportions
of costs. Non-medical costs are divided into costs for informal care and
costs for other non-medical issues comprising formal care, aid/devices
and transportation
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more affected by the disease, but regression analyses showed
that female sex was associated with higher costs, independent
of DAS28 and HAQ. HAQ was similar in men and women at
inclusion, but despite substantial improvement for all patients,
women had higher HAQ scores at all follow ups, and this
could explain some of the differences [10]. There is also a
possibility that women in some cases had the main responsi-
bility for household issues and hence needed more help with
those specific issues.
Onemight assume that non-medical costs could be lower in
the 2006–2009 cohort, compared to the 1996–2008 cohort,
due to more active treatment strategies in the recent decade
[26]. This was, however, not the case. Most costs were similar,
except costs for orthoses, which were significantly higher in
T2. It remains challenging to evaluate if the increasing use of
biologics will affect non-medical resource use over the follow-
ing years [26, 27]. In the present study, biological drugs were
available only for T2, but were prescribed to very few patients
during the first year after diagnosis.
There are a number of limitations in the present study.
The use of self-reported information from questionnaires
may be biased by selective information. The questionnaires
were however kept as diaries over the period, and the pa-
tients registered continuously all medical and non-medical
healthcare utilization.
The T2 questionnaire was slightly revised compared to the
T1, and this lead to some cost components being grouped
differently in the cohorts. For instance, in T2, costs for canes
and crutches were reported separately while in T1, these costs
were included in costs for aids and devices. Costs for work-
place adjustments paid for by the employer was reported in
T1, but not in T2. Although only 4.7% of patients in T1 used
this, the adjustments were rather costly and corresponding
costs are probably not included in any other cost domain in
the T2 questionnaire. Since workplace adjustments for em-
ployees are available to the same extent in 2006–2009 as in
1996–2008, we believe that patients in T2 were likely to have
basically similar average costs paid for by the employer.
However, if costs for work adaptation, for equal comparisons,
are deleted from T1 (or the corresponding value is added to
T2), the difference between the cohorts remains and costs in
T2 increases further compared to T1.
Some patients were offered arrangements by the em-
ployer such as allowing rest periods during the day and
changing the time that work started in the morning. These
measures were difficult to quantify and have not been
taken into account.
A strength of the present study is the well-characterized
patient material and the longitudinal prospective design with
regular follow-ups, allowing analyses of long-term outcomes
in two cohorts of patients with early RA, included from basi-
cally the same catchment area 10 years apart. The bottom-up
approach with questionnaires in our study is also important,
since information on most non-medical costs is available only
through patient-derived data.
To conclude, informal care accounted for the largest part of
non-medical costs and women had higher non-medical costs
than men, during the first year after diagnosis. Despite an
established social welfare system, it is obvious that family
and friends, to a large extent, are involved in informal care
of patients with early RA, and this may underestimate the total
burden of the disease for patient and for society.
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